BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine

The phase III clinical trial of REC603 in China consists of three parts, i.e. the efficacy trial, the immuno-bridging trial in younger-age groups...

August 11, 2022 | News

Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development

Biomedical industry is an important part of Wuxi's modern industrial system construction during the 14th Five-Year Plan(2021-2025) period. Its scale topped...

August 09, 2022 | News

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of ...

August 05, 2022 | News

Lynk Pharmaceuticals Announces IND Approval of LNK01004 for Atopic Dermatitis in China

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple cytokine-induced signaling pathways in vitro and in vivo. LNK01004 is tissue-...

August 04, 2022 | News

ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China

In attendance were founders and representatives from over 100 leading companies and institutions involved in cancer screening and early detection from nume...

August 01, 2022 | News

Lynk Pharmaceuticals Announces First Participants in Phase I Trial of LNK01004

This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...

July 29, 2022 | News

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...

July 27, 2022 | News

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The ...

July 20, 2022 | News

WuXi STA Opens a New Large Scale Continuous Manufacturing Plant

WuXi STA, a subsidiary of WuXi AppTec, announced that it has opened a new continuous manufacturing (flow chemistry) plant at its Changzhou campus in ...

July 20, 2022 | News

China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON

NR082 (rAAV2-ND4), a recombinant adeno-associated viral vector, serotype 2, containing human ND4 codon-optimized gene under the control of the cy...

July 18, 2022 | News

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Dr. Shaoliang Chen, Chair of Pulnovo Medical's Scientific Advisory Board and pioneer of the PADN technology, attended the meeting and presented the co...

July 18, 2022 | News

Merck Launches its Uptune Program in Asia for Collaborating with Startups

Application period for the Merck Uptune program starts today Topics vary from AI-enabled health and cell and gene therapy tools to innovative technologi...

July 15, 2022 | News

Triastek & Lilly to explore the application of 3D printing technology in oral delivery of drugs

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct ...

July 14, 2022 | News

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in les...

July 07, 2022 | News

Stay Connected